Publications

Posters Presented at SITC 2022

Modulating the TME by targeting TGFB1 with vaccine-induced immune responses
Read More

An Arginase-1 peptide-based vaccine is an exciting approach to modulate the TME
Read More

October 2022

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

Nature Medicine, December 2021

Arginase 1-based immune modulatory vaccines induce anti-cancer immunity and synergize with anti-PD-1 checkpoint blockade

Cancer Immunology Research, September 2021

Vaccination against PD-L1 with IO103 a Novel Immune Modulatory Vaccine in Basal Cell Carcinoma: A Phase IIa Study

Cancers, February 2021

Cytotoxic T cells isolated from healthy donors and cancer patients kill TGFβ-expressing cancer cells in a TGFβ-dependent manner

Cellular & Molecular Immunology, January 2021

The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines

OncoImmunology, September 2020

Peptide vaccination directed against IDO1-expressing immune cells elicits CD8+ and CD4+ T-cell-mediated antitumor immunity and enhanced anti-PD1 responses

Journal for Immunotherapy of Cancer, July 2020

Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope

Cancer Immunology & Immunotherapy, November 2019

Peripheral memory T cells speciﬁc for Arginase-1

Cellular & Molecular Immunology, May 2019

Durable clinical responses and long-term follow-up of stage III–IV non-small-cell lung cancer (NSCLC) patients treated with IDO peptide vaccine in a phase I study – A brief research report

Frontiers in Immunology, September 2018

The T-win® technology: immune-modulating vaccines

Seminars in Immunopathology, July 2018

Immunoregulatory antigens – novel targets for cancer immunotherapy

Chinese Clinical Oncology, March 2018

The Balance Players of the Adaptive Immune System

Cancer Research, February 2018

Frequent adaptive immune responses against arginase-1

OncoImmunology, December 2017

The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy

OncoImmunology, August 2017

CCL22 specific T Cells: Modulating the immunosuppressive tumor microenvironment

OncoImmunology, September 2016

Anti-regulatory T cells

Seminars in Immunopathology, September 2016

Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab

Cytotherapy, August 2016

PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine

Oncoimmunology, July 2016

PD-L1-specific T cells

Cancer Immunol Immunotherapy, January 2016

Novel understanding of self-reactive T cells

OncoImmunology, August 2015

Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy

Journal of the National Cancer Institute, June 2015

Tryptophan 2,3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer

OncoImmunology, January 2015

Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase

Clinical Cancer Research. January 2014

Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway

Leukemia, January 2014

HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients

Cancer Research, March 2013

Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators

Blood, February 2011